General
Preferred name
ENASIDENIB MESYLATE
Synonyms
AG221 mesylate ()
AG 221 mesylate ()
AG-221 mesylate ()
Enasidenib (mesylate) ()
AG-221 (mesylate) ()
Idhifa, AG-221 mesylate ()
Idhifa ()
Enasidenib methanesulfonate ()
Enasidenib mesilate ()
CC-90007 ()
P&D ID
PD077737
CAS
1650550-25-6
Tags
available
drug
Drug indication
Acute myeloid leukaemia
Acute myeloid leukemia
Drug Status
approved
Max Phase
4.0
First approval
2017
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes.
PRICE
66
DESCRIPTION
Enasidenib mesylate (AG-221 mesylate) is a potent and selective IDH2 mutase inhibitor that promotes differentiation of leukemia myeloid cells for the treatment of acute myeloid leukemia.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
7
ChEMBL Approved Drugs
ChEMBL Drugs
DrugMAP
DrugMAP Approved Drugs
MedChem Express Bioactive Compound Library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
10
Molecular Weight
569.13
Hydrogen Bond Acceptors
10
Hydrogen Bond Donors
4
Rotatable Bonds
6
Ring Count
3
Aromatic Ring Count
3
cLogP
3.8
TPSA
163.11
Fraction CSP3
0.35
Chiral centers
0.0
Largest ring
6.0
QED
0.25
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
IDH2
Isocitrate Dehydrogenase (IDH)
Dehydrogenase
Pathway
Metabolic Enzyme/Protease
Metabolism
Source data
